Search Results for "Paediatric Study Teriflunomide"
Original Source: Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
The primary objective is to demonstrate that early intervention with Teriflunomide in patients presenting with their first clinical episode consistent with MS prevents or delays conversion to clinically definite Multiple Sclerosis [MS]. The secondary objectives are: - to demonstrate that Teriflunomide prevents or delays conversion to MS based on the revised McDonald Criteria and delays disability progression, - to evaluate the long-term safety of Teriflunom...
Matching Channels
SERAPHIN - STUDY WITH ENDOTHELIN RECEPTOR ANTAGONIST IN PULMONARY ARTERIAL HYPERTENSION TO IMPROVE CLINICAL OUTCOME. SERAPHIN (Study with an Endothelin Rece...
KIACTA™ (also known as eprodisate) is an orally bioavailable small molecule intended for the treatment of AA amyloidosis, an orphan indication that results from long-standing inflammatory cond...
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyle...
Pain is defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in term...
Gynecology is the study of diseases affecting the reproductive organs of women and girls. Add the Gynecology News Channel to your RSS reader;
Matching News
Paediatric Legislation: Challenges And Impact On Drug Development, 20-21 March 2013, London
EU regulations on paediatric drug development are becoming more and more complicated and pharmaceutical companies have to prepare more robust and detailed paediatric investigation plans to ensure the...
Overcoming Obstacles In Paediatric Clinical Trial Design, 20-21 March 2013, London, UK
SMi's 7th annual conference on Paediatric Clinical Trials will discuss new EMA policies and guidelines on paediatric investigation plans as well as focus on clinical trial design and how the industry...
Overcoming Obstacles In Paediatric Clinical Trial Design�, 20-21 March 2013, London, UK
SMi's 7th annual conference on Paediatric Clinical Trials will discuss new EMA policies and guidelines on paediatric investigation plans as well as focus on clinical trial design and how the industry...
Aubagio (teriflunomide) Approved For Multiple Sclerosis Treatment, FDA
Aubagio (teriflunomide), a once-daily tablet for adults with relapsing forms of MS (multiple sclerosis), has been approved by the US Food and Drug Administration (FDA). According to experts, the Multi...
Paediatric rheumatology: Where are the innovations in paediatric rheumatology?
Rapid progress is being made in the field of rheumatology. Nevertheless, disappointingly, the limited resources of the paediatric rheumatology community are being expended on the publication of consen...
TOWER: Teriflunomide Reduces Relapse and Disability in MS
Full results of a phase 3 trial confirm teriflunomide, 14 mg/d, reduces relapse rates and accumulation of disability. Medscape Medical News
The Paediatric Committee (PDCO) of the European Medicines Agency released last year the first ‘5-year Report to the European Commission on the experience acquired on the Paediatric Regulation’.
Paediatric rheumatology: The immaturity of the SLE responder index in paediatric SLE
Matching PubMed Articles
Teriflunomide added to interferon-β in relapsing multiple sclerosis: A randomized phase II trial.
OBJECTIVE: To evaluate teriflunomide as add-on therapy to ongoing stable-dosed interferon-β (IFNβ) in patients with relapsing forms of multiple sclerosis (RMS). METHODS: A total of 118 patients with...
Teriflunomide for treatment of multiple sclerosis.
Interferon beta and glatiramer acetate are still considered to be the first-line therapeutics for treatment of relapsing forms of multiple sclerosis (MS). The use of new compounds, such as natalizumab...
Multiple sclerosis: Teriflunomide shows promise for MS treatment in phase III trial.
Aim: This case control study was to assess whether paediatric dentists perform significantly more diagnostic, preventive and curative care in a clinical setting then do general dental practitioners.
